You are in: eMedicine Specialties > Emergency Medicine > OBSTETRICS AND GYNECOLOGY Abortion, ComplicationsArticle Last Updated: Aug 29, 2006AUTHOR AND EDITOR INFORMATIONAuthor: Slava V Gaufberg, MD, Assistant Professor of Medicine, Harvard Medical School; Associate Chief, Research Director, Director of Education and Training, Department of Emergency Medicine, The Cambridge Hospital Slava V Gaufberg is a member of the following medical societies: American College of Emergency Physicians Editors: Roy Alson, MD, PhD, FACEP, FAAEM, Associate Professor, Department of Emergency Medicine, Wake Forest University School of Medicine; Medical Director, Forsyth County EMS; Deputy Medical Advisor, North Carolina Office of EMS; Associate Medical Director, North Carolina Baptist AirCare; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Mark Zwanger, MD, MBA, Assistant Professor, Department of Emergency Medicine, Thomas Jefferson University; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Pamela L Dyne, MD, Associate Professor, Program Director, Department of Medicine, Division of Emergency Medicine, University of California at Los Angeles School of Medicine Author and Editor Disclosure Synonyms and related keywords: miscarriage, spontaneous abortion, therapeutic abortion, postabortion complications, post-abortion complications, complications of anesthesia, postabortion triad, pain, bleeding, low-grade fever, hematometra, retained products of conception, uterine perforation, bowel and bladder injury, failed abortion, septic abortion, cervical shock, cervical laceration, disseminated intravascular coagulation, DIC, complications of abortion INTRODUCTIONBackgroundComplications of spontaneous and therapeutic abortions include (1) complications of anesthesia, (2) postabortion triad (ie, pain, bleeding, low-grade fever), (3) hematometra, (4) retained products of conception, (5) uterine perforation, (6) bowel and bladder injury, (7) failed abortion, (8) septic abortion, (9) cervical shock, (10) cervical laceration, and (11) disseminated intravascular coagulation (DIC). PathophysiologyPostabortion complications develop as a result of 3 major mechanisms, as follows: (1) incomplete evacuation of the uterus and uterine atony, which leads to hemorrhagic complications, (2) infection, and (3) instrumental injury. FrequencyUnited StatesFrequency depends on gestational age (GA) at time of abortion and method of abortion. Complication rates according to GA at time of abortion are as follows: (1) fewer than 6 weeks, less than 1%; (2) 12-13 weeks, 3-6%; and (3) second trimester, up to 50%, possibly higher. Mortality/MorbidityMortality and morbidity depend on GA at time of abortion. In the US, mortality rates per 100,000 abortions are as follows: (1) fewer than 8 weeks, 0.5; (2) 11-12 weeks, 2.2; (3) 16-20 weeks, 14; and (4) more than 21 weeks, 18. CLINICALHistoryPresentation depends on the type of complication the patient develops.
Physical
DIFFERENTIALSAbortion, Complete Abortion, Incomplete Abortion, Inevitable Abortion, Missed Abortion, Septic Abortion, Threatened Appendicitis, Acute Dysfunctional Uterine Bleeding Dysmenorrhea Ovarian Cysts Ovarian Torsion Pregnancy, Ectopic Pregnancy, Trauma Pregnancy, Urinary Tract Infections Trauma, Lower Genitourinary Urinary Tract Infection, Female Vaginitis Vulvovaginitis
|
| Drug Name | Cefoxitin (Mefoxin) |
|---|---|
| Description | Indicated for infections caused by susceptible gram-positive cocci and gram-negative bacilli. Many infections caused by gram-negative bacteria resistant to some cephalosporins and penicillins respond to cefoxitin. |
| Adult Dose | 2 g IV q6h and 100 mg IV doxycycline q12h; continue at least 4 d and at least 48 h after improvement; then 100 mg PO doxycycline bid 10-14 d |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase effects of cefoxitin; coadministration with aminoglycosides or furosemide may increase nephrotoxicity (closely monitor renal function) |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged use or repeated treatment; caution in patients with previously diagnosed colitis |
| Drug Name | Doxycycline (Bio-Tab, Doryx, Vibramycin) |
|---|---|
| Description | Treats infections caused by susceptible gram-negative and gram-positive organisms, in addition to infections caused by susceptible Rickettsia, Chlamydia, and Mycoplasma species. |
| Adult Dose | 100 mg IV q12h and 2 g IV cefoxitin q6h; continue at least 4 d and at least 48 h after patient improves; then 100 mg PO doxycycline bid 10-14 d |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity, severe hepatic dysfunction |
| Interactions | Bioavailability decreases with antacids containing Al, Ca, Mg, Fe, or Bi subsalicylate; tetracyclines can increase hypoprothrombinemic effects of anticoagulants; tetracyclines can decrease effects of PO contraceptives, causing breakthrough bleeding and increased risk of pregnancy |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; tetracycline use during tooth development (last half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines |
| Drug Name | Gentamicin sulfate (Garamycin, Gentacidin) |
|---|---|
| Description | Aminoglycoside antibiotic for gram-negative coverage. Used in combination with both an agent against gram-positive organisms and an agent that covers anaerobes. Not the DOC. Consider if penicillins (see note above) or other less toxic drugs are contraindicated, when clinically indicated, and in mixed infections caused by susceptible staphylococci and gram-negative organisms. Dosing regimens are numerous; adjust dose based on CrCl and changes in volume of distribution. May be administered IV/IM. |
| Adult Dose | Serious infections and normal renal function: 3 mg/kg/d IV q8h; monitor renal levels Life-threatening infections: 5 mg/kg/d IV q6-8h; monitor renal levels Maintenance dose: 1-2.5 mg/kg IV and 1-1.5 mg/kg IV, respectively, q8h; monitor renal levels |
| Pediatric Dose | >12 years: 1.5-2.5 mg/kg/dose IV q8h or 6-7.5 mg/kg/d IV divided q8h; not to exceed 300 mg/d; monitor renal levels, adjust for renal function as needed; monitor renal levels as in adults |
| Contraindications | Documented hypersensitivity, non–dialysis-dependent renal insufficiency |
| Interactions | Coadministration with other aminoglycosides, cephalosporins, penicillins, and amphotericin B may increase nephrotoxicity; aminoglycosides enhance effects of neuromuscular blocking agents; thus, prolonged respiratory depression may occur; coadministration with loop diuretics may increase auditory toxicity of aminoglycosides; possible irreversible hearing loss of varying degrees may occur (monitor regularly) |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Narrow therapeutic index (not intended for long-term therapy); caution in renal failure (not on dialysis), myasthenia gravis, hypocalcemia, and conditions that depress neuromuscular transmission; adjust dose in renal impairment |
| Drug Name | Ticarcillin and clavulanate potassium (Timentin) |
|---|---|
| Description | Presumptive therapy prior to identification of organism. Inhibits biosynthesis of cell wall mucopeptide; effective during stage of active growth. |
| Adult Dose | <60 kg: 200-300 mg/kg/d IV divided q4-6h >60 kg: 3.1 g IV q4-6h or 200-300 mg/kg/d in equally divided doses q4-6h; not to exceed 18-24 g/d |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; severe pneumonia, bacteremia, pericarditis, emphysema, meningitis, and purulent or septic arthritis should not be treated with PO penicillins during acute stage |
| Interactions | Tetracyclines may decrease effects; high concentrations of ticarcillin may physically inactivate aminoglycosides if administered in same IV line; effects when administered concurrently with aminoglycosides are synergistic; probenecid may increase penicillin levels |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Perform CBCs prior to initiation of therapy and at least weekly during therapy; monitor for liver function abnormalities by measuring AST and ALT during therapy; exercise caution in patients diagnosed with hepatic insufficiencies; perform UA and BUN and creatinine determinations during therapy and adjust dose if values become elevated; monitor blood levels to avoid possible neurotoxic reactions |
| Drug Name | Ampicillin and sulbactam sodium (Unasyn) |
|---|---|
| Description | Drug combination of beta-lactamase inhibitor with ampicillin. Covers skin, enteric flora, and anaerobes. Not ideal for nosocomial pathogens. |
| Adult Dose | 1.5 (1 g ampicillin + 0.5 g sulbactam) to 3 g (2 g ampicillin + 1 g sulbactam) IV/IM q6-8h; not to exceed 4 g/d sulbactam |
| Pediatric Dose | Not established for pediatric patients with intra-abdominal infections >40 kg: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid and disulfiram elevate ampicillin levels; allopurinol decreases ampicillin effects and has additive effects on ampicillin rash; may decrease effects of PO contraceptives |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in renal failure; evaluate rash and differentiate from hypersensitivity reaction |
| Drug Name | Imipenem and cilastatin sodium (Primaxin) |
|---|---|
| Description | Treats multiple-organism infections for which other agents lack wide-spectrum coverage or are contraindicated due to potential toxicity. |
| Adult Dose | 250-500 mg IV divided q6h; not to exceed 3-4 g/d, based on severity of infection Alternatively, administer 500-750 mg IM or intra-abdominally q12h |
| Pediatric Dose | 15-25 mg/kg/dose IV q6h; maximum daily dose for fully susceptible organisms is 2 g/d; for infections with moderately susceptible organisms, maximum dose is 4 g/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with cyclosporine may increase CNS adverse effects of both agents; coadministration with ganciclovir may result in generalized seizures |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Adjust dose in renal insufficiency |
| Drug Name | Piperacillin and tazobactam sodium (Zosyn) |
|---|---|
| Description | Treats septicemia caused by susceptible organisms. |
| Adult Dose | 12 g piperacillin + 1.5 g tazobactam IV in equally divided doses of 3 g q6h for 7-10 d |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Tetracyclines may decrease effects of ticarcillin; high concentrations of ticarcillin may physically inactivate aminoglycosides if administered in same IV line; effects when administered concurrently with aminoglycosides are synergistic; probenecid may increase penicillin levels |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Perform CBCs prior to initiation of therapy and at least weekly during therapy; monitor for liver function abnormalities by measuring AST and ALT during therapy; exercise caution in patients diagnosed with hepatic insufficiencies; perform UA and BUN and creatinine determinations during therapy and adjust dose if values become elevated; monitor blood levels to avoid possible neurotoxic reactions |
| Drug Name | Clindamycin (Cleocin) |
|---|---|
| Description | Useful as treatment against aerobic streptococci and most staphylococci. Inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes, causing RNA-dependent protein synthesis to arrest. |
| Adult Dose | Serious infections due to aerobic and anaerobic organisms: 600-1200 mg/d IV divided q6-8h |
| Pediatric Dose | 8-16 mg/kg/d IV divided tid/qid Severe infections: 16-20 mg/kg/d divided tid/qid |
| Contraindications | Documented hypersensitivity; pseudomembranous colitis; hepatic impairment |
| Interactions | Increases duration of neuromuscular blockade, induced by tubocurarine and pancuronium; erythromycin may antagonize effects; antidiarrheals may delay absorption |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis |
| Drug Name | Cefotaxime (Claforan) |
|---|---|
| Description | Treats septicemia and gynecologic infections caused by susceptible organisms. Arrests bacterial cell wall synthesis, which in turn inhibits bacterial growth. |
| Adult Dose | Moderate-to-severe infections: 1-2 g IV/IM q6-8h Life-threatening infections: 1-2 g IV/IM q4h |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase cefotaxime levels; coadministration with furosemide and aminoglycosides may increase nephrotoxicity |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in severe renal impairment; has been associated with severe colitis |
| Drug Name | Vancomycin HCL (Vancocin, Vancoled) |
|---|---|
| Description | Potent antibiotic directed against gram-positive organisms and active against enterococcal species. Useful in the treatment of septicemia and skin structure infections. Indicated for patients who cannot receive or have failed to respond to penicillins and cephalosporins or who have infections with resistant staphylococci. To avoid toxicity, current recommendation is to assay only vancomycin trough levels after the third dose, drawn 0.5 h before next dosing. Doses and dosing intervals may be adjusted based on CrCl. |
| Adult Dose | 500 mg/d to 2 g/d IV tid/qid for 7-10 d |
| Pediatric Dose | 40 mg/kg/d IV divided tid/qid for 7-10 d |
| Contraindications | Documented hypersensitivity |
| Interactions | Erythema, histaminelike flushing and anaphylactic reactions may occur when administered with anesthetic agents; taken concurrently with aminoglycosides, risk of nephrotoxicity may increase above that with aminoglycoside monotherapy; effects in neuromuscular blockade may be enhanced when coadministered with nondepolarizing muscle relaxants |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in renal failure, neutropenia; "red man" syndrome is caused by too rapid IV infusion (dose administered over a few min) but rarely happens when dose given as 2-h administration or as PO or IP administration; red man syndrome is not an allergic reaction |
Ergot derivatives are used for oxytocic effects on uterine muscle. These agents prevent postabortion uterine atony and hemorrhage.
| Drug Name | Ergonovine maleate (Ergotrate Maleate) |
|---|---|
| Description | Prevents and treats postabortal hemorrhage due to uterine atony by producing a firm contraction of the uterus within minutes. Although intended primarily for IM administration, faster response can be achieved through IV administration. However, because IV route produces higher incidence of adverse effects, reserve for emergencies such as excessive uterine bleeding. Severe uterine bleeding may require repeated doses but seldom requires more than 1 injection q2-4h. |
| Adult Dose | 0.2 mg IM/IV repeat q2-4h if needed |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity, not to be used in cases of threatened spontaneous abortion |
| Interactions | Concurrent administration of methylergonovine with vasoconstrictors or other ergot alkaloids may produce additive effect |
| Pregnancy | X - Contraindicated in pregnancy |
| Precautions | Discontinue if ergotism develops; caution in heart disease, hypertension, mitral-valve stenosis, venoatrial shunts, sepsis, obliterative vascular disease, or hepatic or renal impairment |
| Drug Name | Methylergonovine (Methergine) |
|---|---|
| Description | Acts directly on the smooth muscle of the uterus; induces a rapid and sustained tetanic uterotonic effect that reduces bleeding. |
| Adult Dose | 0.2 mg IM Severe uterine bleeding: Repeat doses q2-4h; same dose may be administered IV to produce quicker response; however, because IV route produces higher incidence of adverse effects, reserve for emergencies such as excessive uterine bleeding |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity, glaucoma, Tourette syndrome, anxiety |
| Interactions | Concurrent administration of methylergonovine with vasoconstrictors or other ergot alkaloids may produce additive effect |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in sepsis, obliterative vascular disease, or hepatic or renal insufficiency |
Abortion, Complications excerpt
Article Last Updated: Aug 29, 2006